The most effective peptide for weight loss currently available is tirzepatide, which produced up to 20.9% body weight loss in clinical trials. It works by activating two gut hormone receptors simultaneously, outperforming its closest competitor, semaglutide, which averages about 12% body weight loss. Both are FDA-approved, injectable peptides, and both require a prescription. Beyond these two frontrunners, several other peptides target weight loss through different biological pathways, each with distinct trade-offs worth understanding.
How Weight Loss Peptides Work
Most weight loss peptides mimic natural hormones your gut releases after eating. These hormones signal your brain to feel full, slow the rate your stomach empties, and improve how your body processes blood sugar. The result is that you eat less without the constant hunger that derails most diets. The two main hormone systems targeted are GLP-1 (which controls appetite and blood sugar) and GIP (which influences how your body stores and burns fat). Some peptides hit one of these targets, others hit both, and a new generation is adding a third.
Tirzepatide: The Current Leader
Tirzepatide, sold as Zepbound for weight loss, activates both GLP-1 and GIP receptors. In the SURMOUNT-1 trial, participants on the highest dose lost 20.9% of their body weight over 72 weeks, compared to just 3.1% in the placebo group. Even the lowest dose produced 15% weight loss. Those numbers represent a meaningful leap over older single-target peptides.
You inject tirzepatide under the skin once a week. The dose gradually increases over several months, which helps your body adjust and reduces side effects. The dual-receptor approach appears to do something that targeting GLP-1 alone does not: it may help your body become more efficient at burning fat rather than simply suppressing appetite, though researchers are still working out exactly why the combination is so potent.
Semaglutide: The Most Studied Option
Semaglutide, marketed as Wegovy for weight management, is a GLP-1 receptor agonist and the most widely studied weight loss peptide available. A 2024 meta-analysis of randomized controlled trials found that semaglutide reduced body weight by an average of 12.1% compared to placebo in people without diabetes. An oral version is also FDA-approved, making it the only weight loss peptide that doesn’t require injections.
Like tirzepatide, semaglutide is a once-weekly injection. The extensive research behind it means clinicians have a clearer picture of its long-term safety profile, which matters if you’re considering staying on treatment for years. The trade-off is simply that it produces less weight loss than tirzepatide on average, though individual responses vary widely.
Liraglutide: A Daily Alternative
Liraglutide, sold as Saxenda, was one of the first GLP-1 peptides approved specifically for weight management. It targets the same receptor as semaglutide but requires a daily injection rather than a weekly one, and it produces more modest weight loss, typically in the range of 5 to 8%. For people who respond poorly to the newer options or prefer starting with a lower-intensity treatment, liraglutide remains a viable choice. But for most people, the convenience and superior results of weekly peptides have made it a second-line option.
Retatrutide: The Next Generation
Retatrutide is an investigational peptide that targets three hormone receptors: GLP-1, GIP, and glucagon. This triple-agonist approach produced 16.8% body weight loss at the highest dose in a recent phase 3 trial over just 40 weeks, with weight still trending downward at the end of the study. It’s being developed by Eli Lilly and is not yet FDA-approved, but the early data suggest it could eventually surpass tirzepatide. The addition of glucagon receptor activation may enhance calorie burning directly, which the current options don’t do as effectively.
Growth Hormone Peptides for Body Composition
A separate category of peptides targets growth hormone rather than appetite. CJC-1295 and ipamorelin are often used together to stimulate your pituitary gland to release more growth hormone, which in turn can shift your body composition toward more muscle and less fat. Higher circulating growth hormone increases fat burning and supports muscle growth, and a 1999 study found that growth hormone recipients lost more weight and gained more lean body mass than a placebo group.
The catch is that direct clinical evidence for CJC-1295 and ipamorelin specifically is scarce. Most of the supporting research links growth hormone elevation in general to improved body composition, not these peptides in particular. They’re also not FDA-approved for weight loss. They’re available through compounding pharmacies and anti-aging clinics, which means quality control and medical oversight vary significantly.
Tesamorelin is a related peptide that is FDA-approved, but only for reducing excess abdominal fat in people with HIV-related lipodystrophy. It works by stimulating growth hormone release and has shown clear reductions in visceral fat in that specific population. Using it off-label for general weight loss is not well supported by evidence.
MOTS-c: A Mitochondrial Peptide
MOTS-c is a naturally occurring microprotein produced by your mitochondria that improves how your muscles take up glucose and burn energy. In animal studies, administering MOTS-c prevented muscle wasting and enhanced muscle glucose uptake. It works differently from GLP-1 drugs: rather than suppressing appetite, it appears to directly improve how your cells use fuel, functioning almost like an exercise mimetic. Human data is still very limited, making it more of a research curiosity than a practical option right now.
Side Effects to Expect
The most common side effects across all GLP-1 peptides are gastrointestinal: nausea, vomiting, diarrhea, and loss of appetite. These are most pronounced when you first start treatment or when your dose increases, and they tend to fade over the first few weeks at each dose level. The gradual dose escalation built into tirzepatide and semaglutide protocols exists specifically to minimize this adjustment period.
A more subtle concern is that rapid weight loss from any method, peptides included, doesn’t just burn fat. You also lose muscle and bone density. Researchers at Mass General Brigham have found that combining GLP-1 treatment with regular exercise and a high-protein, lower-carbohydrate diet significantly reduces muscle loss. The mechanism involves ketosis, which blocks a process where your body breaks down muscle to produce glucose. Patients who exercise consistently from the start of treatment have the best outcomes for preserving lean body mass while losing fat.
Comparing Your Options
- Tirzepatide (Zepbound): FDA-approved, once weekly, up to 20.9% weight loss, dual GLP-1/GIP action
- Semaglutide (Wegovy): FDA-approved, once weekly or oral, ~12% weight loss, GLP-1 action, longest safety track record
- Liraglutide (Saxenda): FDA-approved, daily injection, 5 to 8% weight loss, GLP-1 action
- Retatrutide: Not yet approved, once weekly, 16.8%+ weight loss in trials, triple receptor action
- CJC-1295/Ipamorelin: Not FDA-approved for weight loss, daily injection, limited direct evidence, targets body composition via growth hormone
- Tesamorelin: FDA-approved only for HIV lipodystrophy, daily injection, reduces visceral fat
If your primary goal is losing the most weight with the strongest clinical evidence behind it, tirzepatide is the current best option. If you want the longest safety record and flexibility between injection and oral dosing, semaglutide is the strongest choice. Growth hormone peptides occupy a different niche entirely, better suited for people focused on body composition shifts rather than significant scale weight loss. In all cases, the peptide works best when paired with consistent exercise and adequate protein intake to protect muscle mass during the process.